Bullous pemphigoid is the most common autoimmune blistering skin disease, and incidence is on the rise, due at least in part to its association with older age.
1,2 Treatment of bullous pemphigoid presents a challenge to the clinician, as first-line treatment regimens-either oral corticosteroids or whole body application of super-potent topical steroids-result in substantial morbidity and mortality or present logistical challenges in the elderly. 3 Few trials have compared therapies for bullous pemphigoid. A previous landmark study 4 found that whole-body topical application of the super-potent corticosteroid clobetasol propionate was at least as effective as oral prednisone for disease control at 3 weeks (and more effective for extensive disease). Notably, clobetasol proprionate treatment was associated with a significant reduction in mortality over 52 weeks compared with high-dose (1 mg/kg per day) but not medium-dose prednisone (0·5 mg/kg per day). Consistent with dose-dependent systemic absorption of topical steroids, reducing the dose of topical steroids provided a similar degree of disease control but with reduced morbidity and mortality. 5 Tetracyclines have been used in dermatology for some time for their antiinflammatory properties. 6 The only previous study comparing tetracyclines with corticosteroids in bullous pemphigoid was terminated early and the results, although promising, were not statistically significant. 7 In The Lancet, Hywel Williams and colleagues 8 report the results of the largest multicentre trial comparing oral treatments for bullous pemphigoid; the investigators and participating sites should be congratulated for completing this valuable study. Using a non-inferiority trial design, they tested the hypothesis that 200 mg/day oral doxycycline is not inferior in effectiveness to oral prednisolone (0·5 mg/kg per day) and that doxycycline is less likely to result in severe adverse effects. Participants were allowed to apply up to 30 g per week of potent topical corticosteroids to localised lesions for the first 3 weeks, and after 6 weeks. A high proportion of participants were available for analysis at 6 weeks although, perhaps not unexpectedly, a substantial number dropped out by week 52. Rates of withdrawal were balanced between the two treatment groups.
So what were the major findings? The modified intention-to-treat analysis showed that disease control at 6 weeks was achieved by 91% (92 of 101) of participants starting prednisolone compared with 74% (83 of 112) starting doxycycline-an adjusted difference (by baseline severity of bullous pemphigoid and Karnofsky score) of 18·6% (90% CI 11·1-26·1). In terms of safety, this trial underscored the adverse event profile of systemic steroids for bullous pemphigoid: 36% (41 of 113) of participants starting medium-dose oral prednisolone developed a serious adverse event over 52 weeks compared with 18% (22 of 121) of participants starting doxycycline-an adjusted difference of 19·0% (95% CI 7·9-30·1). In agreement with this, and previous studies, 5, 7 treatment-related deaths were greater in the prednisolone group (11 deaths) compared with the doxycycline group (three deaths).
So how should these data be interpreted? Some help is provided within the protocol and statistical analysis plan 9 and by an earlier publication from the group that considers, in advance, possible outcomes from this trial. 10 Additionally, it is important to consider how the trial was powered and how the non-inferiority margins were determined and set. 11, 12 It appears that the trial was primarily powered to detect a 20% difference in grade 3, 4, and 5 side-effects. 9 Achieving a consensus around the setting of the non-inferiority margin is recognised to be challenging. The authors commendably addressed this in part by undertaking a survey of dermatologists through a national group (the UK Dermatology Clinical Trials Network; appendix p 1 8 ). 13 The results of this survey suggested that UK dermatologists were willing to accept a 25% reduction in effectiveness if this was balanced against a 10% reduction in mortality rate for "tetracycline to have potential as a primary treatment for bullous pemphigoid". 13 However, it is not entirely clear how the data from the survey fed into the setting of the primary endpoints or if the sample size was sufficient to detect a clinically relevant non-inferiority effectiveness margin. Nevertheless, it seems reasonable to move to a broader definition of adverse events (including grades 3-5) and to increase this rate to 20%. Although guidelines for the reporting of non-inferiority trials are not entirely consistent, 11 the non-inferiority margin is often informed by the minimally clinically relevant difference 12 (in this case 25% for effectiveness) such that to reject the null hypothesis (and conclude non-inferiority), the trial would need to provide data where the CI does not cross this boundary. However, the authors interpret the 25% difference as a point estimate and extend the noninferiority margin to 37%-quite a large difference but one that was achievable from recruiting 128 participants per group. Together, this suggests that the trial might have been underpowered for non-inferiority at a clinically relevant difference of effectiveness.
Overall, the data look interesting and, for now, we are left with the conclusion that doxycycline is non-inferior to prednisolone in effectiveness at a difference of between 11·1% and 26·1% (as set by a 90% CI). The secondary measures of effectiveness at 6 weeks also supported a difference of more than 30% in favour of prednisolone and the Kaplan-Meier curve of time to change in treatment (appendix p 10) 8 clearly favours oral prednisolone over doxycycline. It would be interesting to investigate whether any baseline clinical features or biomarkers might differentially predict treatment response. Finally, although the authors aimed to restrict the use of topical corticosteroids for symptomatic relief, we do not know whether the amount applied by both groups was the same. Systemic absorption from topical corticosteroids does occur, and this must be kept in mind when interpreting disease control, morbidity, and mortality.
In conclusion, doxycycline is clearly safer than prednisolone for the treatment of bullous pemphigoid and demonstrates a reduced success rate, based on achieving three or fewer blisters, at 6 weeks. The evidence for non-inferiority is subjective, dependent on the definition of the clinically relevant non-inferiority boundary. However, given the natural history of bullous pemphigoid, 3 and previous responses to topical treatment alone, 4, 5 it is rational to deduce that doxycycline is at least partly effective. So how will this trial affect the management of bullous pemphigoid in clinical practice? Importantly, the primary endpoint for effectiveness in this trial was at 6 weeks. So it would seem reasonable to introduce doxycycline initially in combination with potent (or super-potent) 4 topical steroids; if control is inadequate, treatment can then be escalated to systemic steroids (although this was not covered in the trial design). An alternative strategy, identified by the authors as a potential future trial, would be to start all patients on prednisolone to gain initial control, and then consider doxycycline as a potential maintenance treatmentwith patients randomly assigned to continuation of oral corticosteroids or doxycycline. 
